Bristol Myers Squibb moved into the spotlight after a report of merger talks with AstraZeneca. Article 11 described the possible combination as one of the biggest pharma deals ever. It cited AstraZeneca’s market capitalization at $264 billion and Bristol Myers Squibb’s total valuation at $133 billion as of Friday’s close. Those figures imply a potential transaction of exceptional scale, even before any premium is considered.